HHQ16
HHQ16 is an orally active derivative of Astragaloside IV. HHQ16 effectively reverses infarction-induced hypertrophy and heart failure by targeted degrading lnc4012/lnc9456 and antagonizing their effects on G3BP2/NF-κB signaling[1].
Product Specifications
CAS Number
2620471-66-9
UNSPSC
12352005
Target
Drug Derivative
Type
Reference compound
Related Pathways
Others
Applications
Neuroscience-Neuromodulation
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/hhq16.html
Solubility
10 mM in DMSO
Smiles
C[C@@]12[C@](C[C@H](O)[C@]2([H])[C@]3(C)O[C@H](C(C)(C)O)CC3)(C)[C@]4([H])C[C@H](O)[C@@]5([H])C(C)(C)C(F)(F)CC[C@]5(C6)[C@]46CC1
Molecular Formula
C30H48F2O4
Molecular Weight
510.70
References & Citations
[1]Wan J, et al. Astragaloside IV derivative HHQ16 ameliorates infarction-induced hypertrophy and heart failure through degradation of lncRNA4012/9456. Signal Transduct Target Ther. 2023 Oct 19;8 (1) :414.
Shipping Conditions
Room temperature
Scientific Category
Oligonucleotides
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC681188-100 1x 100 µL
SUMO-1 (SUMO1/1188), CF568 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
